<DOC>
	<DOCNO>NCT00632541</DOCNO>
	<brief_summary>Prior clinical trial involve bevacizumab sorafenib demonstrate single agent activity previously treat advanced breast cancer . This trial test combine VEGF inhibition sorafenib bevacizumab less heavily pre-treated patient advance breast cancer .</brief_summary>
	<brief_title>A Phase II Study Bevacizumab + Sorafenib Metastatic Breast Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . Sorafenib 200mg po daily Bevacizumab 5mg/kg every week 1 Cycle = 4 week Imaging every third cycle Acceptable toxicity non-PD = Protocol therapy continue Un-acceptable toxicity PD = Protocol therapy discontinue ECOG Performance Status 0-1 Life Expectancy : least 12 week Hematopoietic : - Platelets &gt; 100 K/mm3 - Absolute neutrophil count ( ANC ) &gt; 1.5 K/mm3 - Hemoglobin &gt; 10 g/dL Hepatic : - Total Bilirubin &lt; 1.5 x ULN - Aspartate aminotransferase ( AST , SGOT ) &lt; 2 x ULN ( 5 x ULN patient know liver involvement ) Renal : - Creatinine &lt; 1.5 x ULN - No proteinuria demonstrate either Urine protein : creatinine ( UPC ) ratio &lt; 1.0 Urine dipstick proteinuria &lt; 2+ Cardiovascular : - No known myocardial infarction , unstable angina , &gt; grade II New York Heart Association ( NYHA ) classification , congestive heart failure , uncontrolled hypertension define SBP &gt; 150 DBP &gt; 100 , &gt; grade II peripheral vascular disease significant vascular disease ( e.g . aortic aneurysm , aortic dissection ) within 12 month prior register protocol therapy . - No uncontrolled clinically significant arrhythmia . NOTE : Controlled atrial fibrillation allow . - LVEF ≥ LLN MUGA ECHO obtain within 28 day prior register protocol therapy . Pulmonary : - No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within 28 day prior register protocol therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologic cytologic diagnosis breast cancer evidence metastatic disease . NOTE : Patients Her2 positive ( 3+ IHC gene amplification FISH ) eligible prior trastuzumab therapy . Must measurable nonmeasurable lesion define Response Evaluation Criteria Solid Tumors ( RECIST ) . Two few prior chemotherapy regimen disease set . NOTE : All adjuvant neoadjuvant chemotherapy consider one regimen . NOTE : Prior hormonal therapy metastatic disease allow . NOTE : Prior radiation therapy allow long irradiated area source evaluable disease . Age &gt; 18 year time consent . Written inform consent HIPAA authorization release personal health information . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 8 week treatment discontinuation . Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . Ability comply study and/or followup procedure . No prior therapy bevacizumab , sorafenib know VEGF inhibitor . No known hypersensitivity component study drug . No forms cancer therapy include radiation , chemotherapy hormonal therapy within 21 day prior register protocol therapy . No history radiologic evidence CNS metastases include previously treat , resect , asymptomatic brain lesion leptominigeal involvement . A head CT MRI must obtain within 28 day prior register protocol therapy . No participation another clinical drug study within 28 day prior register protocol therapy . No known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C No major surgical procedure within 28 day prior register protocol therapy anticipation need major surgical procedure course study . Placement vascular access device breast biopsy consider major surgery . No minor surgical procedure within 7 day prior register protocol therapy . No known history cerebrovascular disease include TIA , stroke subarachnoid hemorrhage . No known history ischemic bowel . No known history deep venous thrombosis pulmonary embolism . No history hypertensive crisis hypertensive encephalopathy . No nonhealing wound fracture . No active infection require parenteral antibiotic . No hemorrhage/bleeding event ≥ CTCAE grade 3 within 28 day prior register protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>